15.1 Antimicrobial Formulary Management and Restriction Strategies

Antimicrobial Formulary Management and Restriction Strategies

Antimicrobial formulary management serves as the foundational structural intervention of health-system antimicrobial stewardship programs (ASPs). A hospital formulary is not merely an inventory catalog of approved pharmaceuticals; it is an evidence-based, continuously updated policy framework designed to optimize clinical outcomes, minimize drug-induced toxicities, curtail healthcare-acquired superinfections, mitigate selective pressure driving antimicrobial resistance, and control institutional expenditures. Managing antimicrobials requires unique governance because unlike other pharmaceutical classes, the administration of an antimicrobial to an individual patient directly influences the microbial ecosystem of the entire healthcare facility.

---

Multidisciplinary Formulary Governance and Decision-Making

Formulary governance operates through an established institutional committee structure. The Pharmacy and Therapeutics (P&T) Committee exercises ultimate voting authority over institutional medication use policies. However, because infectious diseases pharmacotherapy involves rapid diagnostic integration, complex microbiological surveillance, and high-consequence resistance mechanisms, standard practice establishes a specialized Antimicrobial Subcommittee (AMS) reporting directly to the P&T Committee.

                     INSTITUTIONAL STEWARDSHIP GOVERNANCE

                    ┌──────────────────────────────────┐
                    │  Hospital Medical Executive Comm │
                    └────────────────┬─────────────────┘
                                     │
                    ┌────────────────▼─────────────────┐
                    │ Pharmacy & Therapeutics (P&T)    │
                    │            Committee             │
                    └────────────────┬─────────────────┘
                                     │
                    ┌────────────────▼─────────────────┐
                    │    Antimicrobial Subcommittee    │
                    │ (AMS Co-Chairs: ID PharmD & MD)  │
                    └─┬──────────────┬───────────────┬─┘
                      │              │               │
     ┌────────────────▼─┐   ┌────────▼─────────┐   ┌─▼────────────────┐
     │ Clinical Micro   │   │ Infection Control│   │ Clinical Units   │
     │  & Antibiogram   │   │  & Epidemiology  │   │ (ICU, BMT, ED)   │
     └──────────────────┘   └──────────────────┘   └──────────────────┘

Antimicrobial Subcommittee (AMS) Leadership and Membership

The AMS must be co-led by an Infectious Diseases trained physician and an Infectious Diseases clinical pharmacist specialist, reflecting the Centers for Disease Control and Prevention (CDC) Core Elements of Hospital Antibiotic Stewardship. Core voting and consulting members include:

• ID clinical pharmacy specialists and clinical staff pharmacists
• ID attending physicians and pediatric ID subspecialists
• Clinical microbiology laboratory director
• Hospital epidemiologist and infection preventionists
• Quality improvement, patient safety, and clinical informatics specialists
• Nursing leadership and surgical/critical care physician liaisons

Crafting Evidence-Based Antimicrobial Drug Monographs

When a novel antimicrobial entity is considered for formulary addition, the ID pharmacist prepares a rigorous, comprehensive drug monograph. Evaluation extends far beyond vendor promotional material, analyzing multiple technical domains:

1. Comparative Clinical Efficacy:
   • Scrutinize clinical trial designs: Superiority versus non-inferiority trials. Most antimicrobial registration trials utilize non-inferiority margins (Δ = 10% to 12.5%). A successful non-inferiority trial demonstrates only that the new drug is not clinically worse than the comparator by more than the pre-specified margin; it does not prove equivalence or superiority.
   • Evaluate trial populations: Intent-to-treat (ITT), modified intent-to-treat (mITT), clinically evaluable (CE), and microbiologically evaluable (ME) cohorts. Scrutinize whether trials included immunocompromised hosts, severe organ failure, or multidrug-resistant (MDR) pathogens, or whether high-acuity patients were systematically excluded.
   • Endpoint definitions: Early clinical response (at 48–72 hours) versus test-of-cure (TOC) at 7 to 14 days post-therapy.
2. Safety, Tolerability, and Drug Interaction Profiles:
   • Comparative adverse event incidence: Hepatic transaminitis, bone marrow suppression, nephrotoxicity, neurotoxicity, QTc interval prolongation, and mitochondrial toxicity.
   • Black box warnings, post-marketing safety signals, and teratogenicity.
   • Drug-drug interactions mediated by Cytochrome P450 (CYP) isoenzymes (CYP3A4, CYP2C19), P-glycoprotein (P-gp), organic anion/cation transporters (OAT/OCT), or divalent cation chelation.
3. Pharmacokinetic and Pharmacodynamic (PK/PD) Attributes:
   • Pharmacodynamic indices: Peak to MIC ratio ($C_{max}/MIC$ for aminoglycosides), Area under the curve to MIC ratio ($AUC_{24}/MIC$ for vancomycin, fluoroquinolones, polymyxins), or percentage of dosing interval free drug concentration exceeds MIC (% fT > MIC for beta-lactams).
   • Volume of distribution ($V_d$), protein binding, and tissue penetration into deep infection compartments (epithelial lining fluid [ELF], cerebrospinal fluid [CSF], bone, biliary tract, and urine).
   • Potential to suppress resistant mutants by achieving concentrations above the Mutant Selection Window (MSW).
4. Resistance Selection Risk and Institutional Collateral Damage:
   • Propensity to select for hypervirulent Clostridioides difficile (ribotype 027).
   • Risk of inducing chromosomal beta-lactamases (AmpC beta-lactamases in Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii).
   • Selective pressure driving extended-spectrum beta-lactamases (ESBLs), vancomycin-resistant Enterococcus (VRE), or carbapenem-resistant Enterobacterales (CRE).
5. Institutional Epidemiology and Local Antibiogram Compatibility:
   • Analysis of institutional susceptibility patterns over the preceding 3 to 5 years.
   • Molecular characterization of local resistance mechanisms (e.g., prevalence of KPC versus metallo-beta-lactamases [NDM, VIM] versus OXA-48-like carbapenemases in Gram-negative isolates).
6. Total Cost of Care and Pharmacoeconomic Impact:
   • Direct acquisition cost per day versus standard of care (e.g., $1,200/day vs. $45/day).
   • Ancillary supplies, diluent compatibility, infusion duration, and nursing administration time.
   • Mandatory therapeutic drug monitoring (TDM) assays, laboratory tracking, and outpatient parenteral antimicrobial therapy (OPAT) monitoring requirements.
   • Impact on hospital length of stay (LOS), intensive care unit (ICU) discharge velocity, readmission penalties, and avoidance of toxicity-related dialysis.

---

Tiered Antimicrobial Formulary Frameworks

Health systems structure antimicrobials into tiered categories to balance immediate patient access with institutional stewardship control.

                       TIERED FORMULARY SPECTRUM

 ┌────────────────────────────────────────────────────────────────────────┐
 │ TIER 1: UNRESTRICTED (OPEN ACCESS)                                    │
 │ • Cefazolin, Ceftriaxone, Ampicillin, Metronidazole, Vancomycin (load)│
 │ • Safe, cost-effective, targeted spectrum, minimal collateral damage   │
 └───────────────────────────────────┬────────────────────────────────────┘
                                     │ Escalation
 ┌───────────────────────────────────▼────────────────────────────────────┐
 │ TIER 2: RESTRICTED WITH PRE-AUTHORIZATION (FRONT-END)                  │
 │ • Ceftazidime-avibactam, Cefiderocol, Meropenem-vaborbactam            │
 │ • Requires ID approval prior to dispensing; stops inappropriate starts │
 └───────────────────────────────────┬────────────────────────────────────┘
                                     │ Alternative / Companion
 ┌───────────────────────────────────▼────────────────────────────────────┐
 │ TIER 3: RESTRICTED WITH PROSPECTIVE AUDIT & FEEDBACK (BACK-END)       │
 │ • Meropenem, Cefepime, Daptomycin, Echinocandins                       │
 │ • Open empiric initiation; audited at 48–72h using culture results    │
 └────────────────────────────────────────────────────────────────────────┘

1. Unrestricted (Open Access) Tier

Comprises first-line agents with narrow or well-defined broad spectra, proven safety records, low acquisition costs, and minimal risk of driving institutional ecological damage. Examples include cefazolin, ceftriaxone, ampicillin, ampicillin-sulbactam, and metronidazole. Any licensed prescriber may order these agents without secondary approval.

2. Restricted with Pre-authorization (Front-End Restriction)

Pre-authorization mandates that the prescriber obtain approval from an ID physician or designated ID clinical pharmacist before the pharmacy dispenses the medication. If unapproved, the medication cannot be released, or only an emergency single "bridge" dose is issued while consultation occurs.

• Targeted Agents: Reserved, ultra-broad-spectrum, toxic, or high-cost therapies: ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, cefiderocol, plazomicin, posaconazole, isavuconazole, liposomal amphotericin B.
• Operational Advantages:
  • Immediately prevents inappropriate initiation and optimizes empiric selection.
  • Direct, real-time peer-to-peer education between the prescriber and ID specialist.
  • Significantly curtails unnecessary pharmaceutical expenditures and preserves reserved agents for documented multi-drug resistant infections.
• Operational Liabilities:
  • Potential delay in the administration of the first antimicrobial dose, which can increase mortality in severe septic shock.
  • Significant staffing burden and pager fatigue for ID specialists, especially during off-hours, weekends, and holidays.
  • Potential for provider friction, adversarial interactions, and "workaround" prescribing (e.g., prescribers selecting an unrestricted broad-spectrum agent that is clinically less optimal simply to bypass approval hurdles).

3. Restricted with Prospective Audit and Feedback (PAF / Back-End Restriction)

Prospective audit and feedback permits prescribers to initiate the antimicrobial empirically without front-end barriers. An ID pharmacist or stewardship team systematically audits the order at 48 to 72 hours, evaluating mature microbiology culture data, rapid molecular diagnostic results, radiographic changes, and clinical response. The team provides non-punitive, customized recommendations for de-escalation, dose optimization, IV-to-oral step-down, or therapy discontinuation.

• Targeted Agents: High-utilization broad-spectrum agents: cefepime, piperacillin-tazobactam, meropenem, daptomycin, linezolid, micafungin.
• Operational Advantages:
  • Eliminates delays in administering the critical first dose in acute sepsis.
  • Engages prescribers when complete diagnostic information (identification and sensitivities) is finalized.
  • Fosters collaborative collegiality and preserves prescriber clinical autonomy.
• Operational Liabilities:
  • Prescriber compliance is voluntary; recommendations may be declined or ignored.
  • The patient has already received 48 to 72 hours of broad-spectrum exposure, exerting selective ecological pressure and incurring drug acquisition costs.
  • Labor-intensive for stewardship personnel requiring continuous daily EHR patient chart reviews.

4. Post-Prescription Review with Criteria for Use

Criteria for Use (CFU) establish strict, evidence-based indications, dosing regimens, and laboratory monitoring protocols under which an antimicrobial may be ordered. Modern electronic health records (EHRs) enforce CFUs via computerized provider order entry (CPOE):

• Order Sets with Embedded Clinical Pathways: Pre-built ordering bundles for specific syndromes (e.g., severe CAP, neutropenic fever, septic shock) that default to guideline-concordant first-line agents.
• Mandatory Indication Selection: Prescribers must select a validated indication from a drop-down menu upon ordering.
• Hard Stops vs. Soft Stops: Hard stops block order signing if specific laboratory criteria (e.g., documented CRE on blood culture) are absent; soft stops generate clinical warnings and educational reminders but allow the clinician to proceed.

---

Automatic Stop Orders and Default Durations

Historically, antimicrobial therapy was prescribed for arbitrary, prolonged periods (e.g., 10 to 14 days), driving toxicity and resistance. Modern antimicrobial stewardship institutionalizes default order durations and automatic stop policies.

                  EVIDENCE-BASED TREATMENT DURATION TARGETS

 Uncomplicated Cystitis       CAP (Clinically Stable)      Uncomplicated Cellulitis
 ┌────────────────────┐       ┌────────────────────┐       ┌────────────────────┐
 │     3 – 5 Days     │       │     3 – 5 Days     │       │       5 Days       │
 └────────────────────┘       └────────────────────┘       └────────────────────┘
 Pyelonephritis (FQ)          HAP / VAP                    Source-Controlled cIAI
 ┌────────────────────┐       ┌────────────────────┐       ┌────────────────────┐
 │       7 Days       │       │       7 Days       │       │       4 Days       │
 └────────────────────┘       └────────────────────┘       └────────────────────┘
 Surgical Prophylaxis: Strictly ≤ 24 Hours (or at skin closure post-operatively)

Automatic Duration Caps by Indication

1. Empiric Antimicrobial "Time-Out" (48 to 72 Hours):
   • All empiric broad-spectrum orders carry an automated EHR expiration at 48 to 72 hours.
   • Prescribers must actively review culture data, document clinical infection status, and re-authorize or de-escalate therapy. If not renewed, the medication automatically expires.
2. Perioperative Surgical Antimicrobial Prophylaxis (24 Hours):
   • Supported by ASHP/IDSA/SIS guidelines and Centers for Medicare & Medicaid Services (CMS) quality measures.
   • Prophylaxis must be discontinued at surgical incision closure or strictly within 24 hours post-operatively (48 hours for cardiothoracic procedures).
   • Administering antibiotics beyond 24 hours provides zero additional reduction in surgical site infections (SSIs) while markedly increasing acute kidney injury and C. difficile colitis.
3. Targeted Syndromic Order Duration Caps:
   • Uncomplicated Urinary Tract Infection (Cystitis): 3 days (trimethoprim-sulfamethoxazole), 5 days (nitrofurantoin), or 1 single dose (fosfomycin).
   • Acute Uncomplicated Pyelonephritis: 7 days for oral fluoroquinolones (ciprofloxacin, levofloxacin); 10 to 14 days for oral beta-lactams.
   • Community-Acquired Pneumonia (CAP): 3 to 5 days, provided the patient achieves clinical stability (afebrile for ≥ 48 hours, normal heart rate, respiratory rate, and blood pressure, absorbing oral intake).
   • Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP): 7 days for responding patients, regardless of whether the offending organism is Pseudomonas aeruginosa or Enterobacterales.
   • Uncomplicated Skin and Soft Tissue Infections (Cellulitis): 5 days for patients responding clinically.
   • Complicated Intra-Abdominal Infection (cIAI): 4 days following adequate surgical source control (based on the landmark STOP-IT trial).

---

Dose Optimization and Therapeutic Interchange Policies

P&T-approved therapeutic interchange and dose optimization policies authorize clinical pharmacists to modify orders autonomously based on approved institutional protocols without contacting the ordering physician for individual authorization.

1. Extended and Continuous Infusion Beta-Lactam Protocols

Beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams) display time-dependent bactericidal pharmacodynamics, where efficacy is governed by the percentage of the dosing interval that unbound serum drug concentrations exceed the minimum inhibitory concentration (% fT > MIC).

• Standard Intermittent Infusions: Typically administered over 30 minutes. Serum concentrations peak rapidly and then decline below the MIC well before the end of the interval, particularly for organisms with elevated MICs or in patients with augmented renal clearance (ARC, CrCl > 130 mL/min).
• Extended Infusions: Infused over 3 to 4 hours. By flattening the peak concentration and extending the infusion duration, the proportion of time above MIC is substantially increased across the dosing window without altering the total daily drug exposure.
• Clinical Protocols:
  • Piperacillin-Tazobactam: 3.375 g or 4.5 g IV infused over 4 hours every 8 hours (renally adjusted to 3.375 g IV over 4 hours every 12 hours for CrCl < 50 mL/min).
  • Meropenem: 1 g or 2 g IV infused over 3 hours every 8 hours.
  • Cefepime: 2 g IV infused over 3 to 4 hours every 8 hours (or continuous infusion 6 g IV over 24 hours).
• Physicochemical Stability Caveat: Reconstituted solutions must maintain stability at room temperature during extended administration. Piperacillin-tazobactam and cefepime maintain adequate room-temperature stability for 4 hours; meropenem hydrolyzes rapidly at ambient temperatures and must be infused within 3 to 4 hours of compounding.

2. Automatic IV-to-Oral (PO) Conversion Protocols

Intravenous-to-oral step-down protocols authorize pharmacists to convert stable patients from IV to oral therapy once predefined clinical criteria are satisfied.

• Mandatory Clinical Eligibility Criteria:
  • Functional gastrointestinal tract (tolerating oral diet or enteral tube feedings without high gastric residuals).
  • Hemodynamic stability (afebrile or defervescing, normal blood pressure, absence of vasopressor infusions).
  • Improving clinical biomarkers (normalizing white blood cell count, down-trending C-reactive protein or procalcitonin).
  • Absence of clinical contraindications: Active severe gastrointestinal bleeding, malabsorption syndromes, short bowel syndrome, continuous nasogastric suction, severe intractable vomiting, or refractory ileus.
• Class 1 High-Bioavailability Candidates (> 90% to 100% Oral Bioavailability):

3. Pharmacist-Managed Consult Services

• Renal Function Dose Adjustment: Autonomous pharmacist modification of drug dosing based on estimated glomerular filtration rate, measured 24-hour urine creatinine clearance, or continuous renal replacement therapy (CRRT) operational parameters (effluent flow rates).
• Vancomycin and Aminoglycoside Pharmacokinetic Consults: Full pharmacist delegation for loading doses, maintenance interval design, AUC24 calculation (Bayesian estimation or 2-point kinetic equations), and follow-up lab scheduling.

---

Antimicrobial Drug Shortage Management

Antimicrobial supply chain disruptions represent severe systemic threats to health-system stewardship. Managing shortages requires structured, proactive algorithms rather than reactive crisis improvisation.

                      DRUG SHORTAGE CONSERVATION STRATEGY

 ┌────────────────────────────────────────────────────────────────────────┐
 │ SURVEILLANCE: Daily tracking of ASHP & FDA Shortage Databases          │
 └───────────────────────────────────┬────────────────────────────────────┘
                                     │ Identification of Deficit
 ┌───────────────────────────────────▼────────────────────────────────────┐
 │ TIER 1 CONSERVATION: Reserve Remaining Inventory Strictly For          │
 │ Non-Substitutable Clinical Indications                                  │
 │ • Example: Piperacillin-tazobactam for Febrile Neutropenia with P.     │
 │   aeruginosa risk; Cefazolin for Anaphylactic-Safe Surgical Prophylaxis│
 └───────────────────────────────────┬────────────────────────────────────┘
                                     │ Widespread Shortage
 ┌───────────────────────────────────▼────────────────────────────────────┐
 │ TIER 2 & 3 MITIGATION: Implement Evidence-Based Therapeutic Substitutes│
 │ • Switch empiric sepsis: Cefepime + Metronidazole OR Meropenem         │
 │ • Implement automatic IV-to-PO conversions; split vials under USP <797>│
 └────────────────────────────────────────────────────────────────────────┘

Shortage Surveillance and Operational Protocols

1. Surveillance and Inventory Auditing:
   • Continual monitoring of the American Society of Health-System Pharmacists (ASHP) and Food and Drug Administration (FDA) Drug Shortage Databases.
   • Calculation of "days of supply on hand" based on historic institutional consumption rates.
2. Tier-Based Conservation Algorithms:
   • Tier 1 (Non-Substitutable / Critical Indications): Drug inventory is locked in central pharmacy and restricted exclusively to clinical scenarios where therapeutic alternatives do not exist or carry inferior survival outcomes (e.g., reserving piperacillin-tazobactam for high-risk febrile neutropenia or cystic fibrosis exacerbations with known resistance to cefepime).
   • Tier 2 (Moderate Flexibility): Direct prescribers to validated alternative agents for common infections (e.g., substituting cefepime plus metronidazole, or aztreonam plus metronidazole for intra-abdominal infections).
   • Tier 3 (Broad Alternatives): Transition all uncomplicated cases to alternative classes (e.g., utilizing oral agents, reserving carbapenems strictly for ESBL-confirmed isolates).
3. Pharmacy Compounding and Batching Innovations:
   • Implementation of vial-splitting protocols in the cleanroom under USP <797> sterile compounding standards to eliminate residual drug wastage from single-dose vials.
   • Dose-rounding policies: Rounding doses within 5% to 10% of the prescribed dose to align with standardized commercial vial sizes.
   • Extending beyond-use dating (BUD) using validated stability testing and cold storage.
   • Modifying EHR order entry screens: Suppressing unavailable medications from general preference lists and defaulting to approved shortage substitution regimens.